Axovant to Present at Upcoming Conferences in June
May 31 2019 - 7:00AM
Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage
company developing innovative gene therapies, today announced that
Pavan Cheruvu, M.D., chief executive officer, will present at three
conferences in June.
- Annual Roivant Pipeline DayPresentation date / time: Thursday,
June 6, 2019 at 2:25 p.m. ET
- 2019 Jefferies Global Healthcare ConferencePresentation date /
time: Friday, June 7, 2019 at 11:00 a.m. ET
- The JMP Securities Life Sciences ConferenceFireside chat date /
time: Thursday, June 20, 2019 at 9:00 a.m. ET
A live webcast of each presentation will be
available in the Events section of Axovant's website at
www.axovant.com. A replay will be available for approximately 30
days following the conference.
About Axovant Gene
Therapies
Axovant, part of the Roivant family of companies, is a
clinical-stage gene therapy company focused on developing a
pipeline of innovative product candidates for debilitating
neurological and neuromuscular diseases. The company’s current
pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2
gangliosidosis (including Tay-Sachs disease and Sandhoff disease),
Parkinson’s disease, oculopharyngeal muscular dystrophy (OPMD),
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Axovant is focused on accelerating product candidates into and
through clinical trials with a team of experts in gene therapy
development and through external partnerships with leading gene
therapy organizations. For more information, visit
www.axovant.com.
About Roivant
Roivant Sciences aims to improve health by rapidly delivering
innovative medicines and technologies to patients. It does this by
building Vants – nimble, entrepreneurial biotech and healthcare
technology companies with a unique approach to sourcing talent,
aligning incentives, and deploying technology to drive greater
efficiency in R&D and commercialization. For more information,
please visit www.roivant.com.
Contacts:
MediaMike BeyerSam Brown Inc.
(312) 961-2502mikebeyer@sambrown.commedia@axovant.com
InvestorsTricia
TruehartAxovant(631) 892-7014investors@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From May 2024 to Jun 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2023 to Jun 2024